Citations (162)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (24)
Magdalini Migkou, Despina Fotiou, Maria Gavriatopoulou & Meletios Athanasios Dimopoulos. (2021) Ibrutinib plus rituximab for the treatment of adult patients with Waldenström’s macroglobulinemia: a safety evaluation. Expert Opinion on Drug Safety 20:9, pages 987-995.
Read now
Read now
Ilias Pessach, Meletios A. Dimopoulos & Efstathios Kastritis. (2021) Managing complications secondary to Waldenström’s macroglobulinemia. Expert Review of Hematology 14:7, pages 621-632.
Read now
Read now
Andrew R. Branagan, Mathew Lei, Steven P. Treon & Jorge J. Castillo. (2021) Clinical application of genomics in Waldenström macroglobulinemia. Leukemia & Lymphoma 62:8, pages 1805-1815.
Read now
Read now
Shayna Sarosiek, Steven P. Treon & Jorge J. Castillo. (2021) Reducing treatment toxicity in Waldenström macroglobulinemia. Expert Opinion on Drug Safety 20:6, pages 669-676.
Read now
Read now
Iuliana Vaxman & Morie Gertz. (2020) Waldenstrom's macroglobulinemia in the era of immunotherapy. Leukemia & Lymphoma 61:6, pages 1292-1304.
Read now
Read now
Yan-Hua Zheng, Li Xu, Chun Cao, Juan Feng, Hai-Long Tang, Mi-Mi Shu, Guang-Xun Gao & Xie-Qun Chen. (2019) Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis. OncoTargets and Therapy 12, pages 2751-2766.
Read now
Read now
David H. Vesole, Joshua Richter, Noa Biran, Laura McBride, Palka Anand, Mei Huang, Anita-Zahlten Kumeli, Zandra Klippel, Karim Iskander & David S. Siegel. (2018) Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. Leukemia & Lymphoma 59:1, pages 259-261.
Read now
Read now
Jithma P Abeykoon, Uday Yanamandra & Prashant Kapoor. (2017) New developments in the management of Waldenström macroglobulinemia. Cancer Management and Research 9, pages 73-83.
Read now
Read now
Giulia Benevolo, Maura Nicolosi, Elisa Santambrogio & Umberto Vitolo. (2017) Current options to manage Waldenström’s macroglobulinemia. Expert Review of Hematology 10:7, pages 637-647.
Read now
Read now
Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis & Meletios A. Dimopoulos. (2017) Current treatment options and investigational drugs for Waldenstrom’s Macroglobulinemia. Expert Opinion on Investigational Drugs 26:2, pages 197-205.
Read now
Read now
Jonas Paludo & Stephen M Ansell. (2016) Waldenström macroglobulinemia: biology, genetics, and therapy. Blood and Lymphatic Cancer: Targets and Therapy 6, pages 49-58.
Read now
Read now
Isabelle Herth, Manfred Hensel, Michael Rieger, Kristin Horstmann, Wolfgang Hiddemann, Martin Dreyling, Silvia Koniczek, Mathias Witzens-Harig & Anthony D. Ho. (2015) Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström’s macroglobulinemia. Leukemia & Lymphoma 56:1, pages 97-102.
Read now
Read now
Morie Gertz. (2013) Waldenström macroglobulinemia: my way. Leukemia & Lymphoma 54:3, pages 464-471.
Read now
Read now
Kasyapa S. Chitta, Aneel Paulus, Sikander Ailawadhi, Barbara A. Foster, Michael T. Moser, Petr Starostik, Aisha Masood, Taimur Sher, Kena C. Miller, Dan M. Iancu, Jeffrey Conroy, Norma J. Nowak, Sheila N. Sait, David A. Personett, Morton Coleman, Richard R. Furman, Peter Martin, Stephen M. Ansell, Kelvin Lee & Asher A. Chanan-Khan. (2013) Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute – Waldenström Macroglobulinemia 1. Leukemia & Lymphoma 54:2, pages 387-396.
Read now
Read now
Pierre Morel & Giampaolo Merlini. (2012) Risk stratification in Waldenström macroglobulinemia. Expert Review of Hematology 5:2, pages 187-199.
Read now
Read now
Jack D Burton & David M Goldenberg. (2010) New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma. Expert Opinion on Emerging Drugs 15:4, pages 569-583.
Read now
Read now
Stefan Peinert & John F. Seymour. (2010) Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia. Leukemia & Lymphoma 51:10, pages 1767-1770.
Read now
Read now
Meghan Rourke, Kenneth C. Anderson & Irene M. Ghobrial. (2010) Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leukemia & Lymphoma 51:10, pages 1779-1792.
Read now
Read now
David M. Goldenberg, Franck Morschhauser & William A. Wegener. (2010) Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leukemia & Lymphoma 51:5, pages 747-755.
Read now
Read now
Jennifer Stedman, Aldo Roccaro & Irene M Ghobrial. (2009) Individualizing treatment for Waldenstrom’s macroglobulinemia. Expert Review of Hematology 2:5, pages 473-476.
Read now
Read now
Beate Hauptrock & Georg Hess. (2008) Rituximab in the treatment of non-Hodgkin’s lymphoma. Biologics: Targets and Therapy 2:4, pages 619-633.
Read now
Read now
Aldo M Roccaro, Irene M Ghobrial, Simona Blotta, Steven P Treon, Michele Malagola, Kenneth C Anderson, Paul G Richardson & Domenico Russo. (2008) Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics: Targets and Therapy 2:3, pages 419-431.
Read now
Read now
Aaron Polliack, Koen van Besien & John F. Seymour. (2008) 2007: The year in review for Leukemia and Lymphoma. Leukemia & Lymphoma 49:1, pages 1-3.
Read now
Read now
Stephen A Johnson. (2006) Advances in the treatment of Waldenström’s macroglobulinemia. Expert Review of Anticancer Therapy 6:3, pages 329-334.
Read now
Read now
Articles from other publishers (138)
Bushra Ghafoor, Shameera Shaik Masthan, Maha Hameed, Hafiza Huda Akhtar, Azeem Khalid, Sana Ghafoor, Hassan min Allah, Mohammad Mohsin Arshad, Iman Iqbal, Ahmad Iftikhar, Muhammad Husnain & Faiz Anwer. (2023) Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects. Annals of Hematology.
Crossref
Crossref
Morie A. Gertz. (2023) Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. American Journal of Hematology 98:2, pages 348-358.
Crossref
Crossref
Qingqing Pan, Xinxin Cao, Yaping Luo, Jian Li & Fang Li. (2022) Baseline 18F-FDG PET/CT May Portend the Prognosis of Patients With Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma After First-Line Treatment. Clinical Nuclear Medicine 47:11, pages 954-960.
Crossref
Crossref
Marina Deodato, Anna Maria Frustaci, Giulia Zamprogna, Giulia Cotilli, Roberto Cairoli & Alessandra Tedeschi. (2022) Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy?. Hemato 3:4, pages 689-703.
Crossref
Crossref
Rayan Kaedbey, Nicholas Forward, Laurie H. Sehn, Mona Shafey, Sarah Doucette & Christine I. Chen. (2022) A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia. Current Oncology 29:10, pages 7122-7139.
Crossref
Crossref
Morie A. Gertz. (2022) Waldenstrom Macroglobulinemia: Tailoring Therapy for the Individual. Journal of Clinical Oncology 40:23, pages 2600-2608.
Crossref
Crossref
Sheeba K. Thomas. (2022) SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions. Clinical Lymphoma Myeloma and Leukemia 22:6, pages 347-355.
Crossref
Crossref
Despina Fotiou, Foteini Theodorakakou & Efstathios Kastritis. (2022) Monoclonal antibody-based therapies for Waldenström's macroglobulinemia. Leukemia Research Reports 17, pages 100324.
Crossref
Crossref
Gayathri Ravi & Prashant Kapoor. (2022) Current approach to Waldenström Macroglobulinemia. Cancer Treatment and Research Communications 31, pages 100527.
Crossref
Crossref
Morie A. Gertz. (2021) Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. American Journal of Hematology 96:2, pages 258-269.
Crossref
Crossref
Christian Buske & Véronique Leblond. 2021. Indolent Lymphomas. Indolent Lymphomas
143
161
.
Seri Jeong, Seom Gim Kong, Da Jung Kim, Sangjin Lee & Ho Sup Lee. (2020) Incidence, prevalence, mortality, and causes of death in Waldenström macroglobulinemia: a nationwide, population-based cohort study. BMC Cancer 20:1.
Crossref
Crossref
Jorge J Castillo, Ranjana H Advani, Andrew R Branagan, Christian Buske, Meletios A Dimopoulos, Shirley D'Sa, Marie José Kersten, Veronique Leblond, Monique C Minnema, Roger G Owen, M Lia Palomba, Dipti Talaulikar, Alessandra Tedeschi, Judith Trotman, Marzia Varettoni, Josephine M Vos, Steven P Treon & Efstathios Kastritis. (2020) Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. The Lancet Haematology 7:11, pages e827-e837.
Crossref
Crossref
Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Kenshi Suzuki, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Ryota Shiibashi & Koji Izutsu. (2020) A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia. Cancer Science 111:9, pages 3327-3337.
Crossref
Crossref
Sheeba K. Thomas. (2020) Waldenström Macroglobulinemia – 2020 Update on Management and Future Directions. Clinical Lymphoma Myeloma and Leukemia 20, pages S39-S41.
Crossref
Crossref
Jorge J. Castillo, Joshua N. Gustine, Andrew Keezer, Kirsten Meid, Catherine A. Flynn, Toni E. Dubeau, Gloria Chan, Jiaji Chen, Maria G. Demos, Maria L. Guerrera, Cristina Jimenez, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J. Patterson, Lian Xu, Guang Yang, Zachary R. Hunter & Steven P. Treon. (2020) Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia. American Journal of Hematology 95:4, pages 372-378.
Crossref
Crossref
Yao-Ko Wen. (2020) Rapidly progressive immunoglobulin M monoclonal gammopathy presenting with nephrotic syndrome and hepatic failure. Saudi Journal of Kidney Diseases and Transplantation 31:6, pages 1399.
Crossref
Crossref
Jeremy S. Abramson. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1926
1947.e5
.
S. Vincent Rajkumar & Angela Dispenzieri. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1884
1910.e7
.
Jorge J. Castillo & Steven P. Treon. (2019) What is new in the treatment of Waldenstrom macroglobulinemia?. Leukemia 33:11, pages 2555-2562.
Crossref
Crossref
Alexander Grunenberg & Christian Buske. (2019) Rituximab and ibrutinib in the treatment of Waldenström’s macroglobulinemia. Future Oncology 15:23, pages 2687-2697.
Crossref
Crossref
Alessandra Tedeschi, Concetta Conticello, Rita Rizzi, Giulia Benevolo, Luca Laurenti, Maria Teresa Petrucci, Francesco Zaja & Marzia Varettoni. (2018) Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia. Hematological Oncology 37:2, pages 117-128.
Crossref
Crossref
Morie A. Gertz. (2018) Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. American Journal of Hematology 94:2, pages 266-276.
Crossref
Crossref
Lena Brandefors, Beatrice Melin, Jack Lindh, Kristina Lundqvist & Eva Kimby. (2018) Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study. British Journal of Haematology 183:4, pages 564-577.
Crossref
Crossref
Kimon V. Argyropoulos & M. Lia Palomba. (2018) First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America 32:5, pages 853-864.
Crossref
Crossref
Andres Dominguez, Efstathios Kastritis & Jorge J. Castillo. (2018) Monoclonal Antibodies for Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America 32:5, pages 841-852.
Crossref
Crossref
Steven P. TreonJoshua GustineKirsten MeidGuang YangLian XuXia LiuMaria DemosAmanda KofidesNicholas TsakmaklisJiaji G. ChenManit MunshiGloria ChanToni DubeauNoopur RajeAndrew YeeElizabeth O’DonnellZachary R. HunterJorge J. Castillo. (2018) Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. Journal of Clinical Oncology 36:27, pages 2755-2761.
Crossref
Crossref
Steven P Treon & Jorge J Castillo. (2018) The real world of Waldenström's macroglobulinaemia. The Lancet Haematology 5:7, pages e275-e276.
Crossref
Crossref
Laurence Simon, Marine Baron & Véronique Leblond. (2018) How we manage patients with Waldenström macroglobulinaemia. British Journal of Haematology 181:6, pages 737-751.
Crossref
Crossref
Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni E. Dubeau, Patricia Severns, Lian Xu, Guang Yang, Zachary R. Hunter & Steven P. Treon. (2018) Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. British Journal of Haematology 181:1, pages 77-85.
Crossref
Crossref
Steven P. Treon, Jorge J. Castillo, Zachary R. Hunter & Giampaolo Merlini. 2018. Hematology. Hematology
1419
1431.e5
.
Steven P. Treon, Giampaolo Merlini & Meletios Dimopoulos. 2018. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood
617
638
.
Steven P. Treon, Giampaolo Merlini & Meletios A. Dimopoulos. 2018. Multiple Myeloma and Other Plasma Cell Neoplasms. Multiple Myeloma and Other Plasma Cell Neoplasms
191
220
.
Ya-Ping Zhang, Xi Yang, Zeng-Hua Lin, Xin-Feng Wang, Xin Cao, Xue-Fen You, Hong-Ming Huang, Wen-Yu Shi & Hong Liu. (2017) Low-dose bortezomib and dexamethasone as primary therapy in elderly patients with Waldenstrӧm macroglobulinemia. European Journal of Haematology 99:6, pages 489-494.
Crossref
Crossref
Steven P. Treon & Jorge J. Castillo. (2017) What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy. Blood Advances 1:25, pages 2486-2490.
Crossref
Crossref
Adam J. Olszewski, Chang Chen, Roee Gutman, Steven P. Treon & Jorge J. Castillo. (2017) Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia. British Journal of Haematology 179:1, pages 106-115.
Crossref
Crossref
Jonas Paludo, Jithma P. Abeykoon, Shaji Kumar, Amanda Shreders, Sikander Ailawadhi, Morie A. Gertz, Taxiarchis Kourelis, Rebecca L. King, Craig B. Reeder, Nelson Leung, Robert A. Kyle, Francis K. Buadi, Thomas M. Habermann, David Dingli, Thomas E. Witzig, Angela Dispenzieri, Martha Q. Lacy, Ronald S. Go, Yi Lin, Wilson I. Gonsalves, Rahma Warsame, John A. Lust, S. Vincent Rajkumar, Stephen M. Ansell & Prashant Kapoor. (2017) Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. British Journal of Haematology 179:1, pages 98-105.
Crossref
Crossref
Veronika Bachanova, Robert Frank Cornell & Linda J. Burns. 2017. Hematopoietic Cell Transplants. Hematopoietic Cell Transplants
384
391
.
. 2017. Hematopoietic Cell Transplants. Hematopoietic Cell Transplants
361
444
.
Seongseok Yun, Ariel C. Johnson, Onyemaechi N. Okolo, Stacy J. Arnold, Ali McBride, Ling Zhang, Rachid C. Baz & Faiz Anwer. (2017) Waldenström Macroglobulinemia: Review of Pathogenesis and Management. Clinical Lymphoma Myeloma and Leukemia 17:5, pages 252-262.
Crossref
Crossref
Morie A. Gertz. (2017) Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. American Journal of Hematology 92:2, pages 209-217.
Crossref
Crossref
Maria GavriatopoulouRamón García-SanzEfstathios KastritisPierre MorelMarie-Christine KyrtsonisEurydiki MichalisZafiris KartasisXavier LeleuGiovanni PalladiniAlessandra Tedeschi, Dimitra GikaGiampaolo MerliniPieter Sonneveld & Meletios A. Dimopoulos. (2017) BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood 129:4, pages 456-459.
Crossref
Crossref
Richard R Furman, Herbert A Eradat, Christine G DiRienzo, Craig C Hofmeister, Suzanne R Hayman, John P Leonard, Morton Coleman, Ranjana Advani, Asher Chanan-Khan, Julie Switzky, Qiming M Liao, Damini Shah, Roxanne C Jewell, Steen Lisby & Thomas S Lin. (2017) Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. The Lancet Haematology 4:1, pages e24-e34.
Crossref
Crossref
Michelle Afkhami, Tanya Siddiqi & Steven T. Rosen. 2017. Management of Lymphomas: A Case-Based Approach. Management of Lymphomas: A Case-Based Approach
97
109
.
Véronique Leblond, Laetitia Souchet, Sylvain Choquet & Christian Buske. 2017. Waldenström’s Macroglobulinemia. Waldenström’s Macroglobulinemia
315
326
.
Pierre Morel & Bénédicte Hivert. 2017. Waldenström’s Macroglobulinemia. Waldenström’s Macroglobulinemia
279
293
.
Stephen M. Ansell. 2017. Biology and Management of Unusual Plasma Cell Dyscrasias. Biology and Management of Unusual Plasma Cell Dyscrasias
71
93
.
Adam J. Olszewski, Steven P. Treon & Jorge J. Castillo. (2016) Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis. The Oncologist 21:11, pages 1377-1386.
Crossref
Crossref
Véronique LeblondEfstathios KastritisRanjana AdvaniStephen M. AnsellChristian BuskeJorge J. CastilloRamón García-SanzMorie GertzEva KimbyCharalampia KyriakouGiampaolo MerliniMonique C. MinnemaPierre MorelEnrica MorraMathias Rummel, Ashutosh Wechalekar, Christopher J. PattersonSteven P. TreonMeletios A. Dimopoulos. (2016) Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia. Blood 128:10, pages 1321-1328.
Crossref
Crossref
Jonathan J. Hogan & Brendan M. Weiss. (2016) Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance. Clinical Journal of the American Society of Nephrology 11:9, pages 1681-1691.
Crossref
Crossref
A. Santos-Lozano, A. Morales-Gonzalez, F. Sanchis-Gomar, C. Cristi-Montero, C. Fiuza-Luces, H. Pareja-Galeano, J. Martínez-López, N. Garatachea & A. Lucia. (2016) Response rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials. Critical Reviews in Oncology/Hematology 105, pages 118-126.
Crossref
Crossref
Jorge J. Castillo, M. Lia Palomba, Ranjana Advani & Steven P. Treon. (2016) Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Therapeutic Advances in Hematology 7:4, pages 179-186.
Crossref
Crossref
Efstathios Kastritis & Meletios A. Dimopoulos. (2016) Current therapy guidelines for Waldenstrom's macroglobulinaemia. Best Practice & Research Clinical Haematology 29:2, pages 194-205.
Crossref
Crossref
Prashant Kapoor, Stephen M. Ansell & Esteban Braggio. 2016. Plasma Cell Dyscrasias. Plasma Cell Dyscrasias
321
361
.
Prashant Kapoor, Jonas Paludo, Nishanth Vallumsetla & Philip R. Greipp. (2015) Waldenström macroglobulinemia: What a hematologist needs to know. Blood Reviews 29:5, pages 301-319.
Crossref
Crossref
Steven P. Treon. (2015) How I treat Waldenström macroglobulinemia. Blood 126:6, pages 721-732.
Crossref
Crossref
Morie A. Gertz. (2015) Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management. American Journal of Hematology 90:4, pages 346-354.
Crossref
Crossref
A Oza & S V Rajkumar. (2015) Waldenstrom macroglobulinemia: prognosis and management. Blood Cancer Journal 5:3, pages e394-e394.
Crossref
Crossref
Jorge J. Castillo, Irene M. Ghobrial & Steven P. Treon. 2015. Non-Hodgkin Lymphoma. Non-Hodgkin Lymphoma
177
195
.
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra. (2014) Overview on clinical trials in Waldenstrom's macroglobulinemia. Clinical Investigation 4:12, pages 1139-1154.
Crossref
Crossref
Steven P. Treon, Zachary R. Hunter, Jorge J. Castillo & Giampaolo Merlini. (2014) Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America 28:5, pages 945-970.
Crossref
Crossref
Axel Böhnke & Michael Wenger. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1909
2022
.
Leonard T HeffnerJrJr. (2014) Waldenström macroglobulinemia at 70. International Journal of Hematologic Oncology 3:4, pages 253-266.
Crossref
Crossref
Roger G. Owen, Guy Pratt, Rebecca L. Auer, Rita Flatley, Charalampia Kyriakou, Michael P. Lunn, Francis Matthey, Helen McCarthy, Feargal P. McNicholl, Saad M. Rassam, Simon D. Wagner, Matthew Streetly & Shirley D'Sa. (2014) Guidelines on the diagnosis and management of Waldenström macroglobulinaemia. British Journal of Haematology 165:3, pages 316-333.
Crossref
Crossref
Laetitia Souchet-Cömpain, Sylvain Choquet, Véronique Leblond & Stéphanie Nguyen. (2014) Current and future therapeutic approach for Waldenström’s macroglobulinemia. Immunotherapy 6:3, pages 333-348.
Crossref
Crossref
Irene M. Ghobrial, Thomas E. Witzig, Morie Gertz, Betsy LaPlant, Suzanne Hayman, John Camoriano, Martha Lacy, P. Leif Bergsagel, Stacey Chuma, Daniel DeAngelo & Steven P. Treon. (2014) Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. American Journal of Hematology 89:3, pages 237-242.
Crossref
Crossref
Ho Sup Lee, Kihyun Kim, Dok Hyun Yoon, Jin Seok Kim, Soo-Mee Bang, Jeong-Ok Lee, Hyeon Seok Eom, Hyewon Lee, Inho Kim, Won Sik Lee, Sung Hwa Bae, Se Hyung Kim, Mark Hong Lee, Young Rok Do, Jae Hoon Lee, Junshik Hong, Ho-Jin Shin, Ji Hyun Lee, Yeung-Chul Mun & Chang-Ki Min. (2014) Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea. BioMed Research International 2014, pages 1-7.
Crossref
Crossref
S. Vincent Rajkumar & Angela Dispenzieri. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1991
2017.e7
.
Véronique Leblond, Giampaolo Merlini, Steven P. Treon, Scott Rodig & Jan Delabie. 2014. Rare Lymphomas. Rare Lymphomas
303
329
.
Stephen M. Ansell, Lucy S. Hodge & Suzanne R. Hayman. 2014. Multiple Myeloma. Multiple Myeloma
289
300
.
Steven P. Treon & Giampaolo Merlini. 2013. Myeloma. Myeloma
190
215
.
Meletios A. DimopoulosRamón García-SanzMaria GavriatopoulouPierre MorelMarie-Christine KyrtsonisEurydiki MichalisZafiris KartasisXavier LeleuGiovanni PalladiniAlessandra Tedeschi, Dimitra GikaGiampaolo MerliniEfstathios KastritisPieter Sonneveld. (2013) Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood 122:19, pages 3276-3282.
Crossref
Crossref
Courtney J. Ensslin, Alyx C. Rosen, Shenhong Wu & Mario E. Lacouture. (2013) Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis. Journal of the American Academy of Dermatology 69:5, pages 708-720.
Crossref
Crossref
Siegfried Janz. (2013) Waldenström Macroglobulinemia: Clinical and Immunological Aspects, Natural History, Cell of Origin, and Emerging Mouse Models. ISRN Hematology 2013, pages 1-25.
Crossref
Crossref
Shingo NOGUCHI, Kazuhiro YATERA, Mitsutaka JINBO, Youko FUKUDA, Kei YAMASAKI, Shuya NAGATA, Toshinori KAWANAMI, Hiroshi ISHIMOTO, Kazuhiko MURAKI, Shiro ONO, Hiroo KAWANO, Yukio WAKITA & Hiroshi MUKAE. (2013) A Case of Primary Lymphoplasmacytic Lymphoma Limited to the Paratracheal Mediastinum気管周囲に限局した縦隔原発リンパ形質細胞性リンパ腫の1例. Journal of UOEH 35:3, pages 213-218.
Crossref
Crossref
Anita D'Souza, Stephen Ansell, Craig Reeder & Morie A. Gertz. (2013) Waldenström macroglobulinaemia: the key questions. British Journal of Haematology 162:3, pages 295-303.
Crossref
Crossref
Lucy S. Hodge & Stephen M. Ansell. (2013) Waldenström’s macroglobulinemia: Treatment approaches for newly diagnosed and relapsed disease. Transfusion and Apheresis Science 49:1, pages 19-23.
Crossref
Crossref
Morie A. Gertz. (2013) Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. American Journal of Hematology 88:8, pages 703-711.
Crossref
Crossref
Irene M. Ghobrial. (2013) Choice of Therapy for Patients With Waldenström Macroglobulinemia. Journal of Clinical Oncology 31:3, pages 291-293.
Crossref
Crossref
Véronique LeblondSteve JohnsonSylvie ChevretAdrian CopplestoneSimon RuleOlivier TournilhacJohn Francis SeymourRussell D. PatmoreDavid WrightPierre MorelMarie-Sarah DilhuydySara WilloughbyCaroline DartigeasMarion MalphettesBruno RoyerMaeve EwingsGuy PrattJulie LejeuneFlorence Nguyen-KhacSylvain ChoquetRoger G. Owen. (2013) Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenström Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma. Journal of Clinical Oncology 31:3, pages 301-307.
Crossref
Crossref
Steven P. Treon & Giampaolo Merlini. 2013. Lymphoma. Lymphoma
83
109
.
Efstathios Kastritis & Meletios A. Dimopoulos. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood
681
699
.
M. Hensel, J. Brust, C. Plöger, D. Schuster, M. L. Memmer, J. Franz-Werner, H.-P. Feustel, A. Karcher, S. Fuxius, F. A. Mosthaf, M. Rieger, A. D. Ho & M. Witzens-Harig. (2012) Excellent long-term survival of 170 patients with Waldenström’s macroglobulinemia treated in private oncology practices and a university hospital. Annals of Hematology 91:12, pages 1923-1928.
Crossref
Crossref
Irene M. Ghobrial, Philippe Moreau, Brianna Harris, Tiffany Poon, Eric Jourdan, Hervé Maisonneuve, Karim A. Benhadji, Anwar M. Hossain, Tuan S. Nguyen, James E. Wooldridge & Veronique Leblond. (2012) A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenström Macroglobulinemia. Clinical Cancer Research 18:18, pages 5043-5050.
Crossref
Crossref
M A Gertz, C B Reeder, R A Kyle & S M Ansell. (2011) Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique. Bone Marrow Transplantation 47:9, pages 1147-1153.
Crossref
Crossref
Morie A. Gertz. (2012) Waldenström Macroglobulinemia: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology 87:5, pages 503-510.
Crossref
Crossref
Alessandra Tedeschi, Giulia Benevolo, Marzia Varettoni, Marta L. Battista, Pier L. Zinzani, Carlo Visco, Vittorio Meneghini, Pietro Pioltelli, Stefano Sacchi, Francesca Ricci, Michele Nichelatti, Francesco Zaja, Mario Lazzarino, Umbero Vitolo & Enrica Morra. (2011) Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia. Cancer 118:2, pages 434-443.
Crossref
Crossref
Meletios A. Dimopoulos & Evangelos Terpos. 2012. Bone Marrow Lymphoid Infiltrates. Bone Marrow Lymphoid Infiltrates
223
236
.
Francesca Merchionne, Pasquale Procaccio & Franco Dammacco. (2011) Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center. Critical Reviews in Oncology/Hematology 80:1, pages 87-99.
Crossref
Crossref
Lukas Weiss, Thomas Melchardt, Daniel Neureiter, Ralf Kemmerling, Sharareh Moshir, Lisa Pleyer, Richard Greil & Alexander Egle. (2011) Complete Remission of Waldenström Macroglobulinemia With Azacitidine and Rituximab. Journal of Clinical Oncology 29:24, pages e696-e698.
Crossref
Crossref
Steven P. Treon, Christina Hanzis, Robert J. Manning, Leukothea Ioakimidis, Christopher J. Patterson, Zachary R. Hunter, Patricia Sheehy & Barry Turnbull. (2011) Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. British Journal of Haematology 154:3, pages 357-362.
Crossref
Crossref
Steven P. TreonJacob D. SoumeraiZachary R. HunterChristopher J. PattersonLeukothea IoakimidisBrad Kahl & Michael Boxer. (2011) Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood 118:2, pages 276-281.
Crossref
Crossref
Ghayas C Issa, Irene M Ghobrial & Aldo M Roccaro. (2011) Novel agents in Waldenström macroglobulinemia. Clinical Investigation 1:6, pages 815-824.
Crossref
Crossref
Efstathios Kastritis, Marie-Christine Kyrtsonis, Evdoxia Hatjiharissi, Argiris Symeonidis, Eurydiki Michalis, Panagiotis Repoussis, Konstantinos Tsatalas, Michael Michael, Anastasia Sioni, Zafiris Kartasis, Ekaterini Stefanoudaki, Michael Voulgarelis, Sosana Delimpasi, Maria Gavriatopoulou, Efstathios Koulieris, Dimitra Gika, Elissavet Vervesou, Konstantinos Konstantopoulos, Garyfalia Kokkini, Athanasios Zomas, Paraskevi Roussou, Nikolaos Anagnostopoulos, Theofanis Economopoulos, Evangelos Terpos, Konstantinos Zervas & Meletios A. Dimopoulos. (2011) No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years. American Journal of Hematology 86:6, pages 479-483.
Crossref
Crossref
Morie A. Gertz. (2011) Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management. American Journal of Hematology 86:5, pages 411-416.
Crossref
Crossref
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy and Radiopharmaceuticals 26:1, pages 1-64.
Crossref
Crossref
Gerald B. Appel, J.a.i. Radhakrishnan & Vivette D. D’Agati. 2011. Brenner and Rector's The Kidney. Brenner and Rector's The Kidney
1192
1277
.
Irene M. Ghobrial, Aldo M. Roccaro & Xavier Leleu. 2011. Bortezomib in the Treatment of Multiple Myeloma. Bortezomib in the Treatment of Multiple Myeloma
123
133
.
Charalampia KyriakouCarmen CanalsJan J. CornelissenGerard SociéRoel WillemzeNorbert IfrahHildegard T. GreinixDidier BlaiseEric DeconinckAugustin FerrantAnton SchattenbergJean-Luc HarousseauAnna SuredaNorbert Schmitz. (2010) Allogeneic Stem-Cell Transplantation in Patients With Waldenström Macroglobulinemia: Report From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology 28:33, pages 4926-4934.
Crossref
Crossref
Steven P. Treon & Giampaolo Merlini. 2011. Management of Hematologic Malignancies. Management of Hematologic Malignancies
207
227
.
Agathoclis Agathocleous, Ama Rohatiner, Simon Rule, Hannah Hunter, Jonathan Paul Kerr, Susan M. Neeson, Janet Matthews, Sandra Strauss, Silvia Montoto, Peter Johnson, John Radford & Andrew Lister. (2010)
Weekly
versus
twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia
. British Journal of Haematology 151:4, pages 346-353.
Crossref
Crossref
Stephen M. Ansell, Robert A. Kyle, Craig B. Reeder, Rafael Fonseca, Joseph R. Mikhael, William G. Morice, P. Leif Bergsagel, Francis K. Buadi, Joseph P. Colgan, David Dingli, Angela Dispenzieri, Philip R. Greipp, Thomas M. Habermann, Suzanne R. Hayman, David J. Inwards, Patrick B. Johnston, Shaji K. Kumar, Martha Q. Lacy, John A. Lust, Svetomir N. Markovic, Ivana N.M. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Vivek Roy, Stephen J. Russell, Kristen E. Detweiler Short, A. Keith Stewart, Carrie A. Thompson, Thomas E. Witzig, Steven R. Zeldenrust, Robert J. Dalton, S. Vincent Rajkumar & Morie A. Gertz. (2010) Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines. Mayo Clinic Proceedings 85:9, pages 824-833.
Crossref
Crossref
Charalampia KyriakouCarmen CanalsDavid SibonJean Yves CahnMajid KazmiWilliam ArceseKarin KolbeNorbert Claude GorinKristy ThomsonNoel MilpiedDietger NiederwieserKarel IndrákPaolo CorradiniAnna SuredaNorbert Schmitz. (2010) High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenström Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology 28:13, pages 2227-2232.
Crossref
Crossref
Meletios A. Dimopoulos, Christine Chen, Efstathios Kastritis, Maria Gavriatopoulou & Steven P. Treon. (2010) Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia. Clinical Lymphoma Myeloma and Leukemia 10:2, pages 110-117.
Crossref
Crossref
Irene M. GhobrialFangxin HongSwaminathan PadmanabhanAshraf BadrosMeghan RourkeRenee LeducStacey ChumaJanet KunsmanDiane WarrenBrianna HarrisAmy SamKenneth C. AndersonPaul G. RichardsonSteven P. TreonEdie WellerJeffrey Matous. (2010) Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology 28:8, pages 1422-1428.
Crossref
Crossref
Irene M. GhobrialMorie GertzBetsy LaPlantJohn CamorianoSuzanne HaymanMartha LacyStacey ChumaBrianna HarrisRenee LeducMeghan RourkeStephen M. AnsellDaniel DeAngeloAngela DispenzieriLeif BergsagelCraig ReederKenneth C. AndersonPaul G. RichardsonSteven P. TreonThomas E. Witzig. (2010) Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology 28:8, pages 1408-1414.
Crossref
Crossref
Kei Kusama, Harutsugu Sodeyama, Taiichi Machida, Akito Nishio & Shinji Nakata. (2010) A Case of Synchronous Double Gastric and Rectal Carcinomas Lymphoplasmacytic Lymphoma responding to Preperative Double Filtration Plasmapheresis. The Japanese Journal of Gastroenterological Surgery 43:2, pages 154-159.
Crossref
Crossref
Morie A. Gertz, Rafat Abonour, Leonard T. Heffner, Philip R. Greipp, Hajime Uno & S. V. Rajkumar. (2009) Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow‐up of the Eastern Cooperative Oncology Group E3A98 trial. British Journal of Haematology 147:5, pages 677-680.
Crossref
Crossref
Steven P. Treon. (2009) How I treat Waldenström macroglobulinemia. Blood 114:12, pages 2375-2385.
Crossref
Crossref
Steven P. TreonLeukothea IoakimidisJacob D. SoumeraiChristopher J. PattersonPatricia SheehyMarybeth NelsonMichael WillenJeffrey MatousJohn MatternIIIIJakow G. DienerGeorge P. KeoghThomas J. MyersAndy BoralAnn BirnerDixie L. EsseltineIrene M. Ghobrial. (2009) Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180. Journal of Clinical Oncology 27:23, pages 3830-3835.
Crossref
Crossref
Franck MorschhauserJohn P. LeonardLuis FayadBertrand CoiffierMarie-Odile PetillonMorton ColemanStephen J. SchusterMartin J.S. DyerHeather HorneNick TeohWilliam A. WegenerDavid M. Goldenberg. (2009) Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results. Journal of Clinical Oncology 27:20, pages 3346-3353.
Crossref
Crossref
Steven P. TreonAndrew R. BranaganLeukothea IoakimidisJacob D. SoumeraiChristopher J. PattersonBarry TurnbullParveen WasiChristos EmmanouilidesStanley R. FrankelAndrew ListerPierre MorelJeffrey MatousStephanie A. Gregory & Eva Kimby. (2009) Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 113:16, pages 3673-3678.
Crossref
Crossref
Meletios A. Dimopoulos, Efstathios Kastritis, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Maria Gavriatopoulou, Anna Tassidou & Evangelos Terpos. (2009) Rituximab-Based Treatments in Waldenström's Macroglobulinemia. Clinical Lymphoma and Myeloma 9:1, pages 59-61.
Crossref
Crossref
Xavier Leleu, Julie Gay, Aldo M. Roccaro, Anne-Sophie Moreau, Stephanie Poulain, Remy Dulery, Berenice Bro Des Champs, Daniela Robu & Irene M. Ghobrial. (2009) Update on therapeutic options in Waldenström macroglobulinemia. European Journal of Haematology 82:1, pages 1-12.
Crossref
Crossref
Robert O. Dillman. 2009. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy
693
709
.
Robert O. Dillman. 2009. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy
303
406
.
Steven P. TreonJacob D. SoumeraiAndrew R. BranaganZachary R. HunterChristopher J. PattersonLeukothea IoakimidisFrederick M. BriccettiMark PasmantierHarvey ZimblerRobert B. CooperMaria MooreJohn HillIIIIAlan RauchLawrence GarboLuis ChuCynthia ChuaStephen H. NantelDavid R. LovettHans BoedekerHenry SonnebornJohn HowardPaul Musto, Bryan T. CiccarelliEvdoxia HatjiharissiKenneth C. Anderson. (2008) Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 112:12, pages 4452-4457.
Crossref
Crossref
Steven P. Treon & Giampaolo Merlini. 2009. Treatment of Multiple Myeloma and Related Disorders. Treatment of Multiple Myeloma and Related Disorders
129
149
.
Arun Vijay & Morie A. Gertz. (2008) Current Treatment Options for Waldenström Macroglobulinemia. Clinical Lymphoma and Myeloma 8:4, pages 219-229.
Crossref
Crossref
Umberto Vitolo, Andrés J.M. Ferreri & Silvia Montoto. (2008) Lymphoplasmacytic lymphoma–Waldenstrom's macroglobulinemia. Critical Reviews in Oncology/Hematology 67:2, pages 172-185.
Crossref
Crossref
Prashant Kapoor, Patricia T. Greipp, William G. Morice, S. Vincent Rajkumar, Thomas E. Witzig & Philip R. Greipp. (2008) Anti-CD20 monoclonal antibody therapy in multiple myeloma. British Journal of Haematology 141:2, pages 135-148.
Crossref
Crossref
Robert L. Haining. 2008. Biopharmaceutical Drug Design and Development. Biopharmaceutical Drug Design and Development
99
120
.
Meletios A. Dimopoulos & Athanasios Anagnostopoulos. (2007) Treatment of Waldenstrom’s Macroglobulinemia. Current Treatment Options in Oncology 8:2, pages 144-153.
Crossref
Crossref
Irene M. Ghobrial, Anne-Sophie Moreau, Xavier Leleu & Meletios A Dimopoulos. 2007. Multiple Myeloma: Translational and Emerging Therapies. Multiple Myeloma: Translational and Emerging Therapies
277
297
.
Meletios Athanasios DimopoulosAthanasios AnagnostopoulosMarie-Christine KyrtsonisKonstantinos ZervasConstantinos TsatalasGaryfallia KokkinisPanagiotis RepoussisArgyris SymeonidisSouzana DelimpasiEirini KatodritouElina VervessouEvridiki MichaliAnastasia PouliDimitra GikaAmalia VassouEvangelos TerposNikolaos AnagnostopoulosTheophanis EconomopoulosGerasimos Pangalis. (2007) Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide. Journal of Clinical Oncology 25:22, pages 3344-3349.
Crossref
Crossref
Arun VijayMorie A. Gertz. (2007) Waldenström macroglobulinemia. Blood 109:12, pages 5096-5103.
Crossref
Crossref
Ellen C. Mullen & Michael Wang. (2007) Recognizing Hyperviscosity Syndrome in Patients With Waldenstrom Macroglobulinemia. Clinical Journal of Oncology Nursing 11:1, pages 87-95.
Crossref
Crossref
Michael Wenger. 2007. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1033
1108
.
Athanasios Anagnostopoulos, Parameswaran N. Hari, Waleska S. Pérez, Karen Ballen, Asad Bashey, Christopher N. Bredeson, César O. Freytes, Robert Peter Gale, Morie A. Gertz, John Gibson, Hartmut Goldschmidt, Hillard M. Lazarus, Philip L. McCarthy, Donna E. Reece, David H. Vesole & Sergio A. Giralt. (2006) Autologous or Allogeneic Stem Cell Transplantation in Patients with Waldenstrom’s Macroglobulinemia. Biology of Blood and Marrow Transplantation 12:8, pages 845-854.
Crossref
Crossref
S. Vincent Rajkumar, Angela Dispenzieri & Robert A. Kyle. (2006) Monoclonal Gammopathy of Undetermined Significance, Waldenström Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment. Mayo Clinic Proceedings 81:5, pages 693-703.
Crossref
Crossref
Anthony D. Ho & Manfred Hensel. (2006) Pentostatin for the Treatment of Indolent Lymphoproliferative Disorders. Seminars in Hematology 43, pages S2-S10.
Crossref
Crossref
Eva Kimby, Steven P. Treon, Athanasios Anagnostopoulos, Meletios Dimopoulos, Ramon Garcia-Sanz, Morie A. Gertz, Stephen Johnson, Veronique LeBlond, Jean-Paul Fermand, David G. Maloney, Giampaolo Merlini, Pierre Morel, Enrica Morra, Gwen Nichols, Enrique M. Ocio, Roger Owen, Marvin Stone & Joan Bladé. (2006) Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's Macroglobulinemia. Clinical Lymphoma and Myeloma 6:5, pages 380-383.
Crossref
Crossref
S. A. Johnson, J. Birchall, C. Luckie, D. G. Oscier & R. G. Owen. (2006) Guidelines on the management of Waldenstrom macroglobulinaemia*. British Journal of Haematology 132:6, pages 683-697.
Crossref
Crossref
Morie A. Gertz. (2005) Waldenström macroglobulinemia: A review of therapy. American Journal of Hematology 79:2, pages 147-157.
Crossref
Crossref
Roger G. Owen, Peter Hillmen & Andy c. Rawstron. (2005) CD52 Expression in Waldenström's Macroglobulinemia: Implications for Alemtuzumab Therapy and Response Assessment. Clinical Lymphoma 5:4, pages 278-281.
Crossref
Crossref
Steven P. Treon, Zachary Hunter & Andrew R. Branagan. (2005) CHOP plus Rituximab Therapy in Waldenström's Macroglobulinemia. Clinical Lymphoma 5:4, pages 273-277.
Crossref
Crossref
Meletios A. Dimopoulos, Athanasios Anagnostopoulos, Constantinos Zervas, Marie C. Kyrtsonis, Athanasios Zomas, Constantinos Bourantas, Nicolaos Anagnostopoulos & Gerassimos Pangalis. (2005) Predictive Factors for Response to Rituximab in Waldenström's Macroglobulinemia. Clinical Lymphoma 5:4, pages 270-272.
Crossref
Crossref
Meletios A. Dimopoulos, Robert A. Kyle, Athanasios Anagnostopoulos & Steven P. Treon. (2005) Diagnosis and Management of Waldenstrom's Macroglobulinemia. Journal of Clinical Oncology 23:7, pages 1564-1577.
Crossref
Crossref